Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.
Any statements contained in this press release that relate to future
plans, events or performance are forward-looking statements that involve
risks and uncertainties including, but not limited to, the risks associated
with the events described in this press release, future clinical
development of Synvista Therapeutics' product candidates, and other risks
identified in Synvista Therapeutics' filings with the Securities and
Exchange Commission. Further information on risks faced by Synvista are
detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual
Report on Form 10-K for the year ended December 31, 2006. These filings are
available on a website maintained by the Securities and Exchange Commission
at http://www.sec.gov. The information contained in this press release is
accurate as of the date indicated. Actual result
|SOURCE Synvista Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved